Patents by Inventor Alexander Hay

Alexander Hay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132467
    Abstract: Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 25, 2024
    Applicant: TMEM16A Limited
    Inventors: Stephen COLLINGWOOD, Jonathan David Hargrave, Duncan Alexander Hay, Clive McCarthy, Thomas Beauregard Schofield, Edward Walker, Naomi Went
  • Patent number: 11923694
    Abstract: A power beaming system delivers electric power in laser light from a first location to a remote second location. The laser light has a high energy intensity level defining a hazardous illumination area and a low energy intensity level defining a safe illumination area. The system includes guard circuitry emitter(s) and corresponding detector(s). The guard circuitry forms a detection area about the hazardous illumination area to detect objects in proximity to the hazardous illumination area. A controller directs the guard and power beam circuitry according to sequentially activated safety modes to operate at a low energy intensity level, to scan in a defined pattern, to adjust operation of the detector(s), and to set guard circuitry parameters based on a time value, an object detection value, or a change to the delivered electric power. An output coupled to the controller and power beam circuitry controllably permits or prevents operation at the high energy intensity level.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: March 5, 2024
    Assignee: LASERMOTIVE, INC.
    Inventors: Thomas J. Nugent, Jr., Jordin T. Kare, Alexander Hay
  • Publication number: 20240067653
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: June 30, 2023
    Publication date: February 29, 2024
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT
  • Patent number: 11739094
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: August 29, 2023
    Assignee: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went
  • Patent number: 11631341
    Abstract: An impactor mechanism for virtual or telepresence surgery comprises a base. An impactor shaft has a first end and a second end, a handle portion being provided at the second end. A rotational joint(s) is between the first end of the impactor shaft and the base, the joint providing two or more rotational degrees of freedom to the impactor shaft. Sensors are in the impactor mechanism for measuring an orientation of the impactor shaft relative to the base, and for measuring at least an impact force on the impactor shaft, for use in virtual surgery.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: April 18, 2023
    Inventors: Andre Blain, Sebastien Delorme, Vincent Masse, Erwan Jouault, Sebastien Jomphe, Alexander Hay
  • Publication number: 20220395512
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 15, 2022
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Publication number: 20220302765
    Abstract: A power beaming system delivers electric power in laser light from a first location to a remote second location. The laser light has a high energy intensity level defining a hazardous illumination area and a low energy intensity level defining a safe illumination area. The system includes guard circuitry emitter(s) and corresponding detector(s). The guard circuitry forms a detection area about the hazardous illumination area to detect objects in proximity to the hazardous illumination area. A controller directs the guard and power beam circuitry according to sequentially activated safety modes to operate at a low energy intensity level, to scan in a defined pattern, to adjust operation of the detector(s), and to set guard circuitry parameters based on a time value, an object detection value, or a change to the delivered electric power. An output coupled to the controller and power beam circuitry controllably permits or prevents operation at the high energy intensity level.
    Type: Application
    Filed: June 7, 2022
    Publication date: September 22, 2022
    Inventors: Thomas J. NUGENT, JR., Jordin T. KARE, Alexander HAY
  • Publication number: 20220224165
    Abstract: A remote power system includes a remote power transmitter arranged to output a power beam in a startup mode and a remote power receiver arranged to receive the power beam. The remote power receiver has a plurality of photovoltaic (PV) cells (or other power converters) mounted to generate electrical power from energy in the power beam, startup power monitoring (SPM) logic to determine, based on electrical power generated by each of the plurality of PV cells, whether or not the remote power transmitter can operate in a high-flux mode, and a receiver-based transmitter circuit arranged to communicate an indication that the remote power transmitter can operate in the high-flux mode.
    Type: Application
    Filed: May 21, 2020
    Publication date: July 14, 2022
    Inventors: Thomas J. NUGENT, Jr., Thomas W. BASHFORD, David BASHFORD, Alexander HAY
  • Publication number: 20220224164
    Abstract: A remote power system includes a remote power transmitter arranged to output a high-flux power beam and a remote power receiver arranged to receive the high-flux power beam. The receiver has a plurality of photo-voltaic (PV) cells mounted to generate electrical power from energy in the high-flux power beam, at least one non-PV structure adjacent to each PV cell, and a plurality of structures to steer flux toward selected ones of the plurality of PV cells and away from selected ones of the at least one non-PV structure.
    Type: Application
    Filed: May 21, 2020
    Publication date: July 14, 2022
    Inventors: Thomas J. NUGENT, Jr., Thomas W. BASHFORD, Alexander HAY, David BASHFORD
  • Patent number: 11370778
    Abstract: The present invention discloses bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives of formula (I) as inhibitors of ENaC and are of use in the treatment of respiratory diseases and conditions, skin conditions or ocular conditions, wherein the respiratory disease or condition is e.g. cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, including non-cystic fibrosis bronchiectasis, and asthma; the skin condition is e.g. psoriasis, atopic dermatitis and ichthyosis; and the ocular condition is e.g. dry eye disease.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: June 28, 2022
    Assignee: Enterprise Therapeutics Limited
    Inventors: Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went, Clive McCarthy
  • Patent number: 11368054
    Abstract: A power beaming system delivers electric power in laser light from a first location to a remote second location. The laser light has a high energy intensity level defining a hazardous illumination area and a low energy intensity level defining a safe illumination area. The system includes guard circuitry emitter(s) and corresponding detector(s). The guard circuitry forms a detection area about the hazardous illumination area to detect objects in proximity to the hazardous illumination area. A controller directs the guard and power beam circuitry according to sequentially activated safety modes to operate at a low energy intensity level, to scan in a defined pattern, to adjust operation of the detector(s), and to set guard circuitry parameters based on a time value, an object detection value, or a change to the delivered electric power. An output coupled to the controller and power beam circuitry controllably permits or prevents operation at the high energy intensity level.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 21, 2022
    Assignee: LaserMotive, Inc.
    Inventors: Thomas J. Nugent, Jr., Jordin T. Kare, Alexander Hay
  • Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Publication number: 20220098167
    Abstract: Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: wherein represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are as defined herein; are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen COLLINGWOOD, Clive MCCARTHY, Duncan Alexander HAY, Jonathan David HARGRAVE, Albert MA, Thomas Beauregard SCHOFIELD, Matthew SMITH, Edward WALKER, Naomi WENT, Peter INGRAM, Christopher STIMSON, Someina KHOR
  • Publication number: 20220098164
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, A, Z1, Z2 and Y are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen COLLINGWOOD, Jonathan David HARGRAVE, Duncan Alexander HAY, Edward WALKER
  • Publication number: 20210188855
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: Enterprise Therapeutics Limited
    Inventors: Clive McCARTHY, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD
  • Publication number: 20210147432
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT
  • Patent number: 10941149
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 9, 2021
    Assignee: Enterprise Therapeutics Limited
    Inventors: Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went
  • Publication number: 20200383988
    Abstract: Compounds of general formula (1): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the N H calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: November 22, 2019
    Publication date: December 10, 2020
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Buxton, Matthew Habgood, Peter Ingram, Chun Yan Ma, Spencer Napier, Abdul Shaikh, Matthew Smith, Christopher Stimson, Edward Walker
  • Publication number: 20200361871
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 19, 2020
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Buxton, Matthew Habgood, Peter Ingram, Chun Yan Ma, Spencer Napier, Abdul Shaikh, Matthew Smith, Christopher Stimson, Edward Walker
  • Publication number: 20200294423
    Abstract: An impactor mechanism for virtual or telepresence surgery comprises a base. An impactor shaft has a first end and a second end, a handle portion being provided at the second end. A rotational joint(s) is between the first end of the impactor shaft and the base, the joint providing two or more rotational degrees of freedom to the impactor shaft. Sensors are in the impactor mechanism for measuring an orientation of the impactor shaft relative to the base, and for measuring at least an impact force on the impactor shaft, for use in virtual surgery.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 17, 2020
    Applicants: OSSIMTECH INC., OSSIMTECH INC.
    Inventors: Andre BLAIN, Sebastien DELORME, Vincent MASSE, Erwan JOUAULT, Sebastien JOMPHE, Alexander HAY